Rosanna Sutherby, Pharm.D.

Segesterone acetate is a laboratory-made derivative of progesterone, a sex hormone used in many hormonal contraceptives

Study eases some of the concern about Crohn's disease and ulcerative colitis creating undue infection risk.

Roche's drug is one of a number competing to become the first Bruton's kinase inhibitors approved as a treatment for multiple sclerosis.

Entyvio (vedolizumab) and Xeljanz (tofacitinib) are the most commonly studied therapies, according to the Pfizer-sponsored review, and when the two were compared, Xeljanz showed higher remission rates.

A positive result for Bruton’s tyrosine kinase inhibitor after the drug had been put on partial clinical hold due to concerns about liver toxicity.

The emergence of biologics and other disease-modifying therapies for UC has changed the face of UC treatment in the last 20 years. However, although the number is decreasing, up to 15% of patients with UC will still require colectomy surgery during their lifetime.

Research has observed a decreased risk of autoimmune disorders, including MS, in people who consume alcohol. However, it is not known whether patients may reduce their alcohol consumption as their disease progresses.

According to a study, increased competition brought about by the emergence of biosimilars in the market has resulted in a CAGR decrease of 5% to 20% in biosimilar and reference product pricing. It is estimated that biosimilars have saved payers, and in the end patients, more than $100 billion over five years.

In a recent study, the investigational drug, PIPE-307, effectively induced OPC differentiation and remyelination in MS donor human brain tissue and an animal model and restored lost function in an MS mouse model.

Intranasal administration is a novel delivery method for the treatment of inflammatory human diseases.

Researchers say depictions of inflammatory bowel disease (IBD). which includes ulcerative colitis, don't reflect the growing the incidence of IBD in older and nonwhite populations.

If approved by the FDA they would join Trodelvy as a treatment for triple-negative breast cancer.

The FDA may approve KarXT, an antipsychotic that does not have the side effects of some other antipsychotics because it does not affect dopamine receptors.

In one key finding of the study, about half of the healthcare professionals listed bowel urgency as one of the top five symptoms that impact patients’ lives, however, only about a quarter of them ranked it as a top three symptom affecting treatment decisions.

In clinical guidelines, TNF inhibitors remain the preferred first-line advanced treatment for UC despite the emergence of new biologics approved for UC and Crohn’s disease. Head-to-head trials comparing the effectiveness of these treatments are scarce.

In a study recently published in BMJ Open Gastroenterology, researchers led by Pernille Dige Ovesen from the department of gastroenterology and hepatology in Copenhagen University Hospital investigated the effect of concomitant corticosteroid therapy on treatment outcomes in patients with UC initiating infliximab.

Researchers completed a phase 2 clinical trial investigating the use of autologous stem cell-derived neural progenitors as a treatment option in patients with progressive forms of multiple sclerosis.

TG Therapeutics, Briumvi’s manufacturer, currently recommends that patients who can get pregnant use an effective method of contraception during treatment with Briumvi and for at least six months after the last Briumvi dose. A pregnancy test before each treatment is also recommended.

Progentos will use the funding to advance its multiple sclerosis (MS) program through human proof of concept clinical studies and expand its small molecule pipeline to other degenerative conditions.

Drug developers hope to get in on the action in the hot-selling weight loss drug class

Major drug companies have been snatching up biotech companies that developing antibody-drug conjugates (ADCs) targeting a variety of cancers.

This data is based off of a study conducted by a group of researchers led by Niklas Frahm from the German Multiple Sclerosis Registry to compare the characteristics of patients with MS who switched from their first disease-modifying therapies (DMT) with those of patients who continued taking their first DMT.

The FDA has approved six with dermatologic indications and more are in late-stage trials.

About 30% of people with Crohn’s disease, but on a population basis, it is rare event.

Home testing for fecal calprotectin, a commonly used marker in IBD diagnosis, and symptom quetionnaires might hasten the diagnosis of inflammatory bowel disease.

Although several clinical trials have confirmed the safety and efficacy of rituximab in oncology and autoimmune disease, and even as off-label use in MS, real-world evidence is still necessary to help guide clinicians and managed care professionals in their treatment and coverage decision-making.

At 12 months, the rate of IBD-related surgeries for the monitored group was 1% versus 7% for the control group.

Drug repurposing has recently emerged as an attractive pathway for developing new treatments due to its relatively fast and cost-efficient trajectory. Because obesity and MS share inflammatory properties, researchers used data from the FDA Adverse Event Reporting System to investigate the association between weight loss-inducing drugs and MS